Not surprisingly, variables that come directly into health contact were more important for efficiency and efficiency payment agreements than for price volume agreements, while financial variables were more relevant to price volume agreements, regardless of the type of agreement signed by the hospital where respondents worked. Edlin R, Hall P, Wallner K, McCabe C. Risk sharing between payers and suppliers through health technology leasing: an affordable and effective reimbursement strategy for innovative technologies? Health value. 2014;17 (4):438-44. doi:10.1016/j.j.j.j.jval.2014.01.010. In addition to analyzing the implementation of risk-sharing contracts, this study also examined the potential synergies between these contracts and the promotion of personalized medicine. In this regard, respondents understood that contracts based on efficiency and effectiveness could be an incentive to use personalized treatments. It is assumed that price volume agreements under this new paradigm remain applicable and could therefore be applied as is currently the case, but without synergy to promote personalized medicine. Maskineh C, Nasser SC. Managed entry agreements for pharmaceuticals in the Middle East and North African countries: experience and perspectives of the payer and manufacturer. Value health problems.
2018;16:33–8. Although there was initial interest in testing some possible associations between the variables, no statistical findings were recommended due to the small sample size. Thus, the analysis was mostly descriptive and exploratory and contributed to the succinct literature on stakeholder perceptions. Perception research is a new and emerging theme, which is being implemented as an alternative to learn about the details of risk-sharing contracts, due to the lack of transparency about the management and results of these contracts. Other authors working in this field have also conducted a descriptible analysis based on a limited number of responses. Nazareth et al.  based their analysis on 27 responders in six countries and found that price volume agreements were generally confidential. Their duration, sales thresholds, medications covered, rebates and their effects on cost savings have generally not been reported. In addition, dunlop et al indicated, based on 66 respondents for five EU countries, that stakeholders viewed these agreements as useful management instruments and that their numbers would increase in the future. Not surprisingly, the effectiveness and efficiency of health technologies were not considered relevant criteria for price/volume agreements (9% and 5%) respectively. However, the relevance of these criteria for efficiency-based contracts was 96% and 71%, respectively 75% and 96% for efficiency-based contracts. EMR (Electronic Medical Record) systems are now able to match costs with care outcomes and provide physicians and other health care professionals with a more in-depth overview of the entire care process, including measures such as: Carlson JJ, Chen S, Garrison LP.